Formulation Partnerships Arecor is actively pursuing formulation development deals, including higher concentration versions of nimacimab and peptide therapies. This signals openness to external development resources and potential for CDMO and CRO services. Position as a partner capable of formulation optimization, analytical method development, stability studies, and technology transfer for clinic and potential commercialization.

Outsourcing Opportunities Given its small size and clinical-stage status, Arecor likely relies on outsourcing for development, manufacturing, and formulation work. This creates opportunities for contract manufacturers and CROs to supply GMP manufacturing, clinical trial materials, QC/QA support, and scalable process transfer. A proactive outreach could present end-to-end development partnerships aligned with their current nimacimab and peptide programs.

Oral GLP-1 Potential Arecor's interest in an oral GLP-1 suggests a need for specialized delivery platforms, bioavailability enhancement, and robust translational support. Vendors with oral formulation, mucosal absorption, and bioanalytical capabilities could help accelerate candidacy progression and regulatory readiness. Propose to discuss collaboration on formulation development, pharmacokinetic characterization, and manufacturing scale-up for oral products.

Clinical Stage Partnerships Arecor's conference activity and multiple formulation collaborations indicate an openness to co-development with biotech and pharma partners. This could be an avenue to position as a strategic development partner for late-stage formulation optimization, device-enabled delivery where applicable, and supply of clinical trial materials.

Market Financing Leverage With a focused but early-stage diabetes and obesity portfolio and modest revenue, Arecor may seek licensing, co-development, or strategic investments with larger players to de-risk programs and accelerate timelines. Potential models include milestone-based licenses, exclusive formulation rights, or joint development agreements that align with nimacimab, peptide therapies, or GLP-1 programs.